The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: transforming activity and specific inhibition of FGFR1 fusion proteins
Open accessAbstract
This report describes 2 patients with a clinical and hematologic diagnosis of chronic myeloid leukemia (CML) in chronic phase who had an acquired t(8;22)(p11;q11). Analysis by fluorescence in situ hybridization (FISH) and reverse transcription-polymerase chain reaction (RT-PCR) indicated that both patients were negative for the BCR-ABL fusion, but suggested that the BCR gene was disrupted. Further FISH indicated a breakpoint within fibroblast growth factor receptor 1 (FGFR1), the receptor tyrosine kinase that is known to be disrupted in a distinctive myeloproliferative disorder, most commonly by fusion to ZNF198. RT-PCR confirmed the presence in both cases of an in-frame messenger RNA fusion between BCR exon 4 and FGFR1 exon 9. Expression of BCR-FGFR1 in the factor-dependent cell line Ba/F3 resulted in interleukin 3-independent clones that grew at a comparable rate to cells transformed with ZNF198-FGFR1. The growth of transformed cells was inhibited by the phosphatidylinositol 3-kinase inhibitor LY294002, the farnesyltransferase inhibitors L744832 and manumycin A, the p38 inhibitors SB202190 and SB203580 but not by the MEK inhibitor PD98059. The growth of BaF3/BCR-FGFR1 and BaF3/ZNF198-FGFR1 was not significantly inhibited by treatment with STI571, but was inhibited by SU5402, a compound with inhibitory activity against FGFR1. Inhibition with this compound was associated with decreased phosphorylation of ERK1/2 and BCR-FGFR1 or ZNF198-FGFR1, and was dose dependent with an inhibitory concentration of 50% of approximately 5 μM. As expected, growth of BaF3/BCR-ABL was inhibited by STI571 but not by SU5402. The study demonstrates that the BCR-FGFR1 fusion may occur in patients with apparently typical CML. Patients with constitutively active FGFR1 fusion genes may be amenable to treatment with specific FGFR1 inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification of Ras farnesyltransferase inhibitors by microbial screening.
Hara, M., Akasaka, K., Akinaga, S., Okabe, M., Nakano, H., Gomez, R., Wood, D., Uh, M., & Tamanoi, F. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.6.2281 · Cited by 257
Cited by
Cellular signaling by fibroblast growth factor receptors
Eswarakumar, V. P., Lax, I., & Schlessinger, J. (2005) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.01.001 · Cited by 1,929
Fibroblast growth factors and their receptors in cancer
Wesche, J., Haglund, K., & Haugsten, E. M. (2011) · Biochemical Journal · doi:10.1042/bj20101603 · Cited by 534
Gavine, P. R., Mooney, L., Kilgour, E., Thomas, A. P., Al-Kadhimi, K., Beck, S., Rooney, C., Coleman, T., Baker, D., Mellor, M. J., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3034 · Cited by 501
Kinase mutations in human disease: interpreting genotype–phenotype relationships
Lahiry, P., Torkamani, A., Schork, N. J., & Hegele, R. A. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2707 · Cited by 420
Fibroblast growth factor signaling in tumorigenesis
Grose, R., & Dickson, C. (2005) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.01.003 · Cited by 404
Metadata
- Authors
- Demiroglu, A., Steer, E. J., Heath, C., Taylor, K., Bentley, M., Allen, S. L., Koduru, P., Brody, J. P., Hawson, G., Rodwell, R., Doody, M.-L., Carnicero, F., Reiter, A., Goldman, J. M., Melo, J. V., & Cross, N. C. P.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2001-12-15
- Volume
- 98
- Issue
- 13
- Pages
- 3778-3783
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2126524003
- Cited by
- 189
- References
- 1
- FWCI
- 4.67
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: transforming activity and specific inhibition of FGFR1 fusion proteins. https://app.cochat.ai/papers/10.1182/blood.v98.13.3778
- The paper
- Demiroglu, A., Steer, E. J., Heath, C., Taylor, K., Bentley, M., Allen, S. L., Koduru, P., Brody, J. P., Hawson, G., Rodwell, R., Doody, M.-L., Carnicero, F., Reiter, A., Goldman, J. M., Melo, J. V., & Cross, N. C. P. (2001). The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: transforming activity and specific inhibition of FGFR1 fusion proteins. Blood. https://doi.org/10.1182/blood.v98.13.3778
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.